🔴 SAB Biotherapeutics is trading 8.1% down in pre-market with no clear company-specific catalyst

SAB Biotherapeutics is trading at $2.39, down 8.08% in pre-market, with no clear company-specific announcement identified to explain the decline.

• SAB Biotherapeutics is scheduled to participate in the Chardan 10th Annual Healthcare Conference on October 20; the event was announced October 14 and does not establish a direct cause for the move.
• Available market data conflicts with the supplied biotech-sector weakness context, so sector pressure cannot be confirmed as the explanation.